Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy.
Blood
; 139(9): 1409-1412, 2022 03 03.
Article
in English
| MEDLINE | ID: covidwho-1608221
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Immunization, Secondary
/
Immunity, Humoral
/
SARS-CoV-2
/
COVID-19
/
BNT162 Vaccine
/
Multiple Myeloma
Type of study:
Cohort study
/
Experimental Studies
/
Observational study
/
Prognostic study
Topics:
Vaccines
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
English
Journal:
Blood
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS